carbamates has been researched along with Alzheimer Disease in 241 studies
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated cerebral glucose metabolism (CMRglc) and cerebrospinal fluid (CSF) levels of tau and beta-amyloid(1-42) (Abeta42), in relation to apolipoprotein E (ApoE) genotype, in patients with mild Alzheimer disease (AD) treated with rivastigmine (n=11) and tacrine (n=16) for 1 year; and two untreated AD groups." | 9.10 | Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. ( Almkvist, O; Blennow, K; Hellström-Lindahl, E; Nordberg, A; Stefanova, E, 2003) |
| "Rate of disease progression for patients with mild to moderate AD seems to predict response to rivastigmine treatment." | 6.70 | Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. ( Anand, R; Farlow, MR; Hake, A; Hartman, R; Messina, J; Veach, J, 2001) |
| "The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs." | 6.42 | Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. ( Prasher, VP, 2004) |
| "Data were collected from patients with Alzheimer's disease who were treated with rivastigmine between 1 October 1998-30 November 1999 at the Memory Disorders Outpatients Clinic at the Academic Medical Centre or the Slotervaart Hospital, both in Amsterdam, the Netherlands." | 5.31 | [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy]. ( Richard, E; van Campen, J; van Gool, WA; Vissers, E; Walstra, GJ, 2002) |
| "We evaluated cerebral glucose metabolism (CMRglc) and cerebrospinal fluid (CSF) levels of tau and beta-amyloid(1-42) (Abeta42), in relation to apolipoprotein E (ApoE) genotype, in patients with mild Alzheimer disease (AD) treated with rivastigmine (n=11) and tacrine (n=16) for 1 year; and two untreated AD groups." | 5.10 | Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. ( Almkvist, O; Blennow, K; Hellström-Lindahl, E; Nordberg, A; Stefanova, E, 2003) |
| "Alzheimer's disease patients with hypertension or other vascular risk factors have been shown to receive greater symptomatic benefits than patients with strictly Alzheimer's disease following short-term treatment with rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase." | 5.10 | Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. ( Andrews, C; Erkinjuntti, T; Lane, R; Skoog, I, 2003) |
| " Beneficial effects with rivastigmine therapy in the functioning of activities of daily living, behavior, cognition, and global functioning have been demonstrated in patients with mild to moderate Alzheimer disease in 4 large double-blind, placebo-controlled multicenter clinical trials." | 4.82 | Update on rivastigmine. ( Farlow, MR, 2003) |
| "In recent years several new treatments have been introduced in neurology, sumatriptan in migraine, riluzole in amyotrophic lateral sclerosis, interferon-beta in multiple sclerosis and rivastigmine in Alzheimer's disease." | 4.80 | [New therapies in neurology, but who benefits?]. ( de Haan, RJ; Vermeulen, M, 1999) |
| " Aging, a natural process of neurodegeneration, was associated with a reduction in Notch-1 signaling in rat cortex and hippocampus, and this was restored with chronic treatment with URB 597." | 3.78 | The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-β and in the cortex of aged rats. ( Bowie, AG; Campbell, VA; Gowran, A; Keating, SE; Noonan, J; Tanveer, R, 2012) |
| " Galantamine is a novel treatment for Alzheimer disease with a dual mode of action." | 3.71 | Maintaining functional and behavioral abilities in Alzheimer disease. ( Winblad, B, 2001) |
| "We report the case of an 81-year-old woman, suffering from a major depressive episode and incipient Alzheimer disease, whom we treated with ECT without interrupting therapy with the acetylcholinesterase inhibitor (ACHE-I) rivastigmine." | 3.71 | Electroconvulsive therapy in a patient receiving rivastigmine. ( Henn, FA; Lederbogen, F; Sartorius, A; Zink, M, 2002) |
| "We hypothesized that restless legs syndrome (RLS), a common neurological sensorimotor disorder of uncomfortable leg sensations that appear at night and interfere with sleep, might be a cause for nighttime agitation in persons with AD." | 2.94 | Nighttime Agitation and Restless Legs Syndrome in Persons With Alzheimer's Disease: Study Protocol for a Double-Blind, Placebo-Controlled, Randomized Trial (NightRest). ( Allen, R; Fry, L; Gooneratne, N; Hanlon, A; Kovach, C; Loera, A; Lozano, A; Morrison, J; Rangel, A; Richards, K; Wang, YY, 2020) |
| "Oestro-progestagen treatment did not provide further improvement when combined with rivastigmine during mild to moderately severe Alzheimer's disease." | 2.71 | [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study]. ( André, G; Loria-Kanza, Y; Pere, JJ; Rigaud, AS; Touchon, J; Vellas, B, 2003) |
| "6 %)treatment was withdrawn because of mostly gastrointestinal adverse events." | 2.71 | Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. ( Bardelli, F; Bencini, F; Biagini, CA; Caleri, V; Cantini, C; Cavallini, MC; Marini, M; Masotti, G; Mecacci, R; Mossello, E; Razzi, E; Sarcone, E; Tilli, S; Tonon, E, 2004) |
| " Nonlinear mixed-effects modeling of pharmacokinetic and pharmacodynamic data was conducted using NONMEM." | 2.70 | Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. ( Cutler, NR; Gobburu, JV; Jhee, SS; Lesko, L; Sramek, JJ; Tammara, V; Yuan, R, 2001) |
| " Rivastigmine was generally well tolerated, the most common adverse events being nausea and vomiting, consistent with reports from previous clinical studies." | 2.70 | Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. ( Auriacombe, S; Loria-Kanza, Y; Pere, JJ; Vellas, B, 2002) |
| "The correlates of dropout, efficacy, and adverse events in the treatment of Alzheimer's disease (AD) with acetylcholinesterase inhibitors (ChEI) are unclear." | 2.70 | Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease. ( Kim, JM; Shin, IS; Yoon, JS, 2002) |
| "Treatment with donepezil reduced the AChE activity (k3 values) in the AD brain by 39% in the frontal (p < 0." | 2.70 | Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. ( Järvenpää, T; Kaasinen, V; Kurki, T; Någren, K; Oikonen, V; Rinne, JO; Roivainen, A; Yu, M, 2002) |
| "Rate of disease progression for patients with mild to moderate AD seems to predict response to rivastigmine treatment." | 2.70 | Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. ( Anand, R; Farlow, MR; Hake, A; Hartman, R; Messina, J; Veach, J, 2001) |
| " Safety was monitored by physical examinations, vital signs, laboratory tests, ECG recording and by the assessment of adverse events." | 2.70 | An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting. ( Barcikowska, M; Bilikiewicz, A; Bilińska, M; Gabryelewicz, T; Ochudło, S; Opala, G; Paradowski, B; Parnowski, T; Pfeffer, A; Podemski, R; Puzyński, S; Sołtys, K; Łapin, J, 2002) |
| "To investigate the bioavailability of rivastigmine, an approved therapy for patients with mild to moderate dementia of the Alzheimer's type, at the highest approved single dose of 6 mg." | 2.70 | Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. ( Cutler, NR; Hossain, M; Jhee, SS; McDonald, C; Pommier, F; Sedek, G; Shiovitz, T, 2002) |
| "Scores on the Alzheimer's disease assessment scale improved in patients in the higher dose group when compared with patients taking placebo (P<0." | 2.69 | Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. ( Agid, Y; Anand, R; Cicin-Sain, A; Dal-Bianco, P; Gauthier, S; Gharabawi, M; Hartman, R; Rösler, M; Stähelin, HB, 1999) |
| "Efficacy measures included the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), the Clinician's Interview Based Impression of Change (CIBIC-Plus), the Progressive Deterioration Scale (PDS), the Global Deterioration Scale (GDS), and the Mini-Mental State Examination (MMSE)." | 2.69 | An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. ( Anand, R; Hartman, R; Kumar, V; Messina, J; Veach, J, 2000) |
| " Most adverse events were mild to moderate in severity and of limited duration, most commonly headache, nausea, dizziness, and diarrhea." | 2.68 | Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. ( Anand, R; Cutler, NR; Hartman, RD; Irwin, P; Sramek, JJ; Wardle, TS, 1996) |
| "Current pharmacotherapy for Alzheimer's disease involves compounds that are aimed at increasing the levels of acetylcholine in the brain by facilitating cholinergic neurotransmission through inhibition of cholinesterase." | 2.43 | Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. ( Castro, A; Martinez, A, 2006) |
| "Therefore, additional therapies for Alzheimer's disease still need to be developed that include more tolerable agents with alternative mechanisms of action and broader efficacy." | 2.42 | Current treatments for Alzheimer's disease: cholinesterase inhibitors. ( Doody, RS, 2003) |
| "The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs." | 2.42 | Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. ( Prasher, VP, 2004) |
| "By some estimates moderate-to-severe Alzheimer's disease accounts for 50% of all patients with Alzheimer's disease." | 2.42 | What are the treatment options for patients with severe Alzheimer's disease? ( Feldman, H; Portet, F; Reynish, E; Vellas, B; Voisin, T, 2004) |
| "At the present time interventions for Alzheimer's disease are limited to those that modify the manifestations of the disease, and foremost amongst the candidates available are the cholinesterase inhibitors." | 2.42 | Evidence-based pharmacotherapy of Alzheimer's disease. ( Birks, J; Evans, JG; Wilcock, G, 2004) |
| "The estimated prevalence of Alzheimer's disease for a standard health authority (500,000 people) is about 3330." | 2.41 | Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. ( Bryant, J; Clegg, A; De Broe, S; Gerard, K; McIntyre, L; Nicholson, T; Waugh, N, 2001) |
| " They occurred mostly during the dosage titration phase and decreased during the maintenance phase." | 2.41 | Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. ( Jann, MW, 2000) |
| " Further resarch is desirable on dosage (frequency and quanitity) in a search for ways to minimize adverse effects." | 2.41 | Rivastigmine for Alzheimer's disease. ( Birks, J; Iakovidou, V; Tsolaki, M, 2000) |
| "The cholinergic hypofunction in Alzheimer's disease (AD) appears to be linked with two other major hallmarks of this disease, beta-amyloid and hyperphosphorylated tau protein." | 2.41 | Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. ( Fisher, A, 2000) |
| " In order to maximize and prolong positive drug effects, it is important to start early and adjust dosage during the treatment." | 2.41 | Cholinesterase inhibitors stabilize Alzheimer's disease. ( Giacobini, E, 2000) |
| "About three-quarters of patients with Alzheimer's disease are admitted to a nursing home within 5 years of diagnosis." | 2.41 | Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease. ( Goa, KL; Lamb, HM, 2001) |
| " They are usually mild-to-moderate, of short duration and responsive to dosage reduction." | 2.41 | Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. ( Desai, A; Grossberg, G, 2001) |
| "During the last years, treatment of Alzheimer's disease has improved following a better detection of this disease and, more importantly, following a better knowledge of its physiopathogeny." | 2.41 | [Anticholinesterase agents in Alzheimer's disease]. ( Sternon, J; Ventura, M, 2001) |
| " Improvement in behavioural symptoms also occurs, but without a dose-response relationship." | 2.41 | Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. ( Jann, MW; Shirley, KL; Small, GW, 2002) |
| "In the absence of a cure for Alzheimer's disease (AD), treatment has focused on therapy to provide symptomatic benefits and to slow progression of the disease, so that patients can maintain their independence for as long as possible." | 2.41 | Do cholinesterase inhibitors slow progression of Alzheimer's disease? ( Farlow, MR, 2002) |
| "A guide for drug prescription in Alzheimer's disease is thus warranted and becomes clearer, sure that, in the next future modifications and new strategies will appear." | 2.41 | [Perspectives for drug treatment in Alzheimer's disease]. ( Allain, H; Bentue-Ferrer, D; Lecavorzin, P; Polard, E; Reymann, JM; Tribut, O, 2001) |
| " Rivastigmine shows a clear dose-response relationship, and physicians should aim to maintain patients on doses of 6 mg/day or higher, to a maximum of 12 mg/day." | 2.41 | The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. ( Bullock, R, 2002) |
| "Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed." | 2.41 | Guidelines for managing Alzheimer's disease: Part II. Treatment. ( Cherry, D; Cummings, JL; Frank, JC; Hewett, L; Kemp, B; Kohatsu, ND; Mittman, B, 2002) |
| " The lower dosage range of 1 to 4 mg/day was not as effective as 6 to 12 mg/day, as measured using these criteria and other efficacy parameters." | 2.40 | Rivastigmine. A review of its use in Alzheimer's disease. ( Noble, S; Spencer, CM, 1998) |
| "Alzheimer's disease is a still untreatable multifaceted pathology, and drugs able to stop or reverse its progression are urgently needed." | 1.46 | Chalcone-based carbamates for Alzheimer's disease treatment. ( Bartolini, M; Belluti, F; Bisi, A; Cavalli, A; Falchi, F; Feoli, A; Gobbi, S; Montanari, S; Pruccoli, L; Rampa, A; Tarozzi, A, 2017) |
| "Anandamide is an endocannabinoid involved in several physiological functions including neuroprotection." | 1.40 | Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: modulation by cannabinoid agonists. ( de Ceballos, ML; Giusto, NM; Martín-Moreno, AM; Pascual, AC; Pasquaré, SJ, 2014) |
| "The cascade of events that occurs in Alzheimer's disease involving oxidative stress and the reduction in cholinergic transmission can be better addressed by multifunctional drugs than cholinesterase inhibitors alone." | 1.38 | Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease. ( Finkin-Groner, E; Ginsburg, I; Lerman, L; Nudelman, A; Shalom, H; Weill, T; Weinstock, M; Yanovsky, I; Zaikin, A; Zeeli, S, 2012) |
| "The aetiology of Alzheimer's disease is thought to include functional impairment of synapses and synapse loss as crucial pathological events leading to cognitive dysfunction and memory loss." | 1.38 | C-terminal fragment of N-cadherin accelerates synapse destabilization by amyloid-β. ( Andreyeva, A; Gottmann, K; Horstmann, K; Klapper, S; Korth, C; Müller-Schiffmann, A; Nieweg, K, 2012) |
| "Transgenic models of Alzheimer's disease (AD) have made significant contributions to our understanding of AD pathogenesis, and are useful tools in the development of potential therapeutics." | 1.37 | Characterization of a Drosophila Alzheimer's disease model: pharmacological rescue of cognitive defects. ( Ansaloni, S; Chakraborty, R; Delvadia, R; Desai, A; Goldstein, LE; Khandelwal, P; Lee, JC; Marenda, DR; Melicharek, DJ; Mhatre, SD; Michelson, SJ; Miller, S; Moir, RD; Paddock, BE; Saunders, AJ; Tabb, LP; Utreja, S; Vepuri, V; Vinokur, M, 2011) |
| "One of the main hallmarks of Alzheimer's disease (AD) is the brain deposition of senile plaques made up of toxic amyloid beta-peptide (Abeta), which is derived from a larger protein called the beta-amyloid precursor protein (APP)." | 1.34 | Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease. ( Alley, GM; Chen, D; Greig, NH; Lahiri, DK; Tweedie, D, 2007) |
| "Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease." | 1.33 | Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819). ( Amari, G; Bartolucci, C; Bolzoni, PT; Delcanale, M; Ghidini, E; Lamba, D; Racchi, M; Siotto, M; Villetti, G, 2006) |
| "were diagnosed with Alzheimer's disease on two occasions or filled a prescription for rivastigmine for the first time during the index period from 1 July 2000 to 31 December 2001; (b)." | 1.32 | Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine. ( Arcona, S; Mirski, D; Powers, C; Rabinowicz, AL; Shin, H; Suh, DC; Thomas, SK, 2004) |
| "Muscle fasciculation appeared only after donepezil with a dose-dependent incidence and intensity." | 1.32 | Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. ( Liang, YQ; Tang, XC, 2004) |
| " Specifically, certain metabolic parameters (ie, half-life and route of metabolism/elimination) can affect a drug's tolerability and become important when a switch from one agent to another is contemplated." | 1.31 | Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. ( Farlow, MR, 2001) |
| " A pharmacodynamic analysis of rivastigmine administered concomitantly with other medications (22 different therapeutic classes) did not reveal any significant pattern of increase in adverse events that would indicate a drug interaction." | 1.31 | Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. ( Anand, R; Grossberg, GT; Messina, JC; Stahelin, HB; Veach, J, 2000) |
| "Differences in scores on the Alzheimer's Disease Assessment Scale-Cognitive Function, Clinician's Interview-Based Impression of Change with both clinical and caregiver information considered, Progressive Deterioration Scale, Mini-Mental State Examination (MMSE), and Global Deterioration Scale were assessed." | 1.31 | Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications. ( Bailey, PA; Baladi, JF; Black, S; Bouchard, RW; Farcnik, KD; Gauthier, S; Kertesz, A; Mohr, E; Robillard, A, 2000) |
| "Data were collected from patients with Alzheimer's disease who were treated with rivastigmine between 1 October 1998-30 November 1999 at the Memory Disorders Outpatients Clinic at the Academic Medical Centre or the Slotervaart Hospital, both in Amsterdam, the Netherlands." | 1.31 | [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy]. ( Richard, E; van Campen, J; van Gool, WA; Vissers, E; Walstra, GJ, 2002) |
| " Safety evaluations were performed 23 hours after drug dosing and at the end of the study." | 1.30 | Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. ( Ebert, MH; Enz, A; Johnson, B; Kennedy, JS; Laplanche, R; Loosen, P; Mancione, LC; Parris, WC; Polinsky, RJ; Schmidt, D, 1999) |
| " These properties suggest that P10358 may be a safe and promising symptomatic treatment for Alzheimer's disease." | 1.30 | Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. ( Bores, GM; Brooks, KM; Camacho, F; Cunningham, DM; Davis, L; Fishkin, R; Hartman, HB; Li, M; Petko, W; Roehr, J; Rush, DK; Selk, DE; Smith, CP; Vargas, HM; Winslow, JT, 1997) |
| "Treatments in Alzheimer's disease include treatment of cognitive impairment and behavioral manifestations (agitation, depression, anxiety, delusions)." | 1.30 | [Drug therapy strategies in Alzheimer's disease]. ( Lacomblez, L, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 31 (12.86) | 18.2507 |
| 2000's | 170 (70.54) | 29.6817 |
| 2010's | 20 (8.30) | 24.3611 |
| 2020's | 20 (8.30) | 2.80 |
| Authors | Studies |
|---|---|
| Kaya-Tilki, E | 1 |
| Dikmen, M | 1 |
| Liu, D | 3 |
| Zhang, H | 6 |
| Wang, Y | 6 |
| Liu, W | 2 |
| Yin, G | 2 |
| Wang, D | 1 |
| Li, J | 3 |
| Shi, T | 2 |
| Wang, Z | 4 |
| Mi, J | 1 |
| He, Y | 1 |
| Yang, J | 1 |
| Zhou, Y | 1 |
| Zhu, G | 1 |
| Wu, A | 1 |
| Sang, Z | 2 |
| Scheiner, M | 2 |
| Sink, A | 1 |
| Hoffmann, M | 3 |
| Vrigneau, C | 1 |
| Endres, E | 2 |
| Carles, A | 1 |
| Sotriffer, C | 2 |
| Maurice, T | 2 |
| Decker, M | 3 |
| Wu, D | 1 |
| Chen, J | 1 |
| Luo, K | 1 |
| Li, H | 1 |
| Liu, T | 1 |
| Li, L | 1 |
| Dai, Z | 1 |
| Li, Y | 3 |
| Zhao, Y | 1 |
| Fu, X | 1 |
| Feng, Y | 1 |
| Lu, Y | 1 |
| Li, Z | 1 |
| Li, X | 2 |
| Long, L | 1 |
| Peng, Y | 1 |
| Qi, F | 1 |
| Jiang, W | 1 |
| Wang, S | 2 |
| Stiller, C | 1 |
| Gunesch, S | 1 |
| Yang, GX | 1 |
| Huang, Y | 1 |
| Zheng, LL | 1 |
| Zhang, L | 1 |
| Su, L | 1 |
| Wu, YH | 1 |
| Zhou, LC | 1 |
| Huang, J | 1 |
| Tang, Y | 1 |
| Wang, R | 1 |
| Ma, L | 3 |
| Bagri, K | 1 |
| Kumar, A | 1 |
| Kumar, P | 1 |
| Richards, K | 1 |
| Morrison, J | 1 |
| Wang, YY | 1 |
| Rangel, A | 1 |
| Loera, A | 1 |
| Hanlon, A | 1 |
| Lozano, A | 1 |
| Kovach, C | 1 |
| Gooneratne, N | 1 |
| Fry, L | 1 |
| Allen, R | 1 |
| Camarillo-López, RH | 1 |
| Hernández Rodríguez, M | 1 |
| Torres-Ramos, MA | 1 |
| Arciniega-Martínez, IM | 1 |
| García-Marín, ID | 1 |
| Correa Basurto, J | 1 |
| Méndez Méndez, JV | 1 |
| Rosales-Hernández, MC | 1 |
| Baswar, D | 1 |
| Sharma, A | 1 |
| Mishra, A | 1 |
| Gentzsch, C | 1 |
| Ohshima, Y | 1 |
| Nose, N | 1 |
| Chen, X | 1 |
| Higuchi, T | 1 |
| Chiurchiù, V | 1 |
| Scipioni, L | 1 |
| Arosio, B | 1 |
| Mari, D | 1 |
| Oddi, S | 1 |
| Maccarrone, M | 2 |
| Shahrivar-Gargari, M | 1 |
| Hamzeh-Mivehroud, M | 1 |
| Hemmati, S | 1 |
| Mojarrad, JS | 1 |
| Tüylü Küçükkılınç, T | 1 |
| Ayazgök, B | 1 |
| Dastmalchi, S | 1 |
| Montanari, S | 3 |
| Allarà, M | 1 |
| Scalvini, L | 2 |
| Kostrzewa, M | 1 |
| Belluti, F | 3 |
| Gobbi, S | 3 |
| Naldi, M | 1 |
| Rivara, S | 2 |
| Bartolini, M | 3 |
| Ligresti, A | 2 |
| Bisi, A | 3 |
| Rampa, A | 3 |
| Grieco, M | 1 |
| De Caris, MG | 1 |
| Maggi, E | 1 |
| Armeli, F | 1 |
| Coccurello, R | 1 |
| Bisogno, T | 1 |
| D'Erme, M | 1 |
| Mancini, P | 1 |
| Businaro, R | 1 |
| Jiang, X | 1 |
| Zhang, Z | 1 |
| Zuo, J | 1 |
| Wu, C | 1 |
| Zha, L | 1 |
| Xu, Y | 1 |
| Shi, J | 1 |
| Liu, XH | 1 |
| Zhang, J | 1 |
| Tang, W | 1 |
| Wu, J | 1 |
| Kou, X | 1 |
| Ju, H | 1 |
| Yang, A | 1 |
| Shen, R | 1 |
| Pruccoli, L | 1 |
| Falchi, F | 1 |
| Feoli, A | 1 |
| Cavalli, A | 1 |
| Tarozzi, A | 1 |
| Tagami, S | 1 |
| Yanagida, K | 1 |
| Kodama, TS | 1 |
| Takami, M | 1 |
| Mizuta, N | 1 |
| Oyama, H | 1 |
| Nishitomi, K | 1 |
| Chiu, YW | 1 |
| Okamoto, T | 1 |
| Ikeuchi, T | 1 |
| Sakaguchi, G | 1 |
| Kudo, T | 1 |
| Matsuura, Y | 1 |
| Fukumori, A | 1 |
| Takeda, M | 2 |
| Ihara, Y | 1 |
| Okochi, M | 2 |
| Toublet, FX | 1 |
| Lecoutey, C | 1 |
| Lalut, J | 1 |
| Hatat, B | 1 |
| Davis, A | 1 |
| Since, M | 1 |
| Corvaisier, S | 1 |
| Freret, T | 1 |
| Sopkova de Oliveira Santos, J | 1 |
| Claeysen, S | 1 |
| Boulouard, M | 1 |
| Dallemagne, P | 1 |
| Rochais, C | 1 |
| Pascual, AC | 1 |
| Martín-Moreno, AM | 1 |
| Giusto, NM | 1 |
| de Ceballos, ML | 1 |
| Pasquaré, SJ | 1 |
| Qiang, X | 1 |
| Xiao, G | 1 |
| Liu, Q | 1 |
| Tan, Z | 1 |
| Deng, Y | 2 |
| Sang, ZP | 1 |
| Qiang, XM | 1 |
| Wu, B | 1 |
| Zhao, MG | 1 |
| Lilja, AM | 2 |
| Malmsten, L | 1 |
| Röjdner, J | 1 |
| Voytenko, L | 1 |
| Verkhratsky, A | 1 |
| Ögren, SO | 1 |
| Nordberg, A | 6 |
| Marutle, A | 2 |
| Andrisano, V | 1 |
| Di Marzo, V | 1 |
| Mor, M | 1 |
| Jones, M | 1 |
| Wang, J | 1 |
| Harmon, S | 1 |
| Kling, B | 1 |
| Heilmann, J | 1 |
| Gilmer, JF | 1 |
| Teng, L | 1 |
| Zhao, J | 1 |
| Wang, F | 1 |
| Pei, G | 1 |
| Lecanu, L | 1 |
| Tillement, L | 1 |
| McCourty, A | 1 |
| Rammouz, G | 1 |
| Yao, W | 1 |
| Greeson, J | 1 |
| Papadopoulos, V | 1 |
| Porras, O | 1 |
| Storelli, E | 1 |
| Chakraborty, R | 1 |
| Vepuri, V | 1 |
| Mhatre, SD | 1 |
| Paddock, BE | 1 |
| Miller, S | 1 |
| Michelson, SJ | 1 |
| Delvadia, R | 1 |
| Desai, A | 2 |
| Vinokur, M | 1 |
| Melicharek, DJ | 1 |
| Utreja, S | 1 |
| Khandelwal, P | 1 |
| Ansaloni, S | 1 |
| Goldstein, LE | 1 |
| Moir, RD | 1 |
| Lee, JC | 1 |
| Tabb, LP | 1 |
| Saunders, AJ | 1 |
| Marenda, DR | 1 |
| Mutoh, T | 1 |
| Kawamura, N | 1 |
| Hirabayashi, Y | 1 |
| Shima, S | 1 |
| Miyashita, T | 1 |
| Ito, S | 1 |
| Asakura, K | 1 |
| Araki, W | 1 |
| Cazzaniga, E | 1 |
| Muto, E | 1 |
| Masserini, M | 1 |
| Andreyeva, A | 1 |
| Nieweg, K | 1 |
| Horstmann, K | 1 |
| Klapper, S | 1 |
| Müller-Schiffmann, A | 1 |
| Korth, C | 1 |
| Gottmann, K | 1 |
| Tanveer, R | 1 |
| Gowran, A | 1 |
| Noonan, J | 1 |
| Keating, SE | 1 |
| Bowie, AG | 1 |
| Campbell, VA | 1 |
| Roy, KK | 1 |
| Tota, S | 1 |
| Tripathi, T | 1 |
| Chander, S | 1 |
| Nath, C | 1 |
| Saxena, AK | 1 |
| Yanovsky, I | 1 |
| Finkin-Groner, E | 1 |
| Zaikin, A | 1 |
| Lerman, L | 1 |
| Shalom, H | 1 |
| Zeeli, S | 1 |
| Weill, T | 1 |
| Ginsburg, I | 1 |
| Nudelman, A | 1 |
| Weinstock, M | 4 |
| Song, H | 1 |
| Boo, JH | 1 |
| Kim, KH | 1 |
| Kim, C | 1 |
| Kim, YE | 1 |
| Ahn, JH | 1 |
| Jeon, GS | 1 |
| Ryu, H | 1 |
| Kang, DE | 1 |
| Mook-Jung, I | 1 |
| Giacobini, E | 2 |
| Spiegel, R | 4 |
| Enz, A | 5 |
| Veroff, AE | 1 |
| Cutler, NR | 5 |
| Wolfson, C | 1 |
| Oremus, M | 1 |
| Shukla, V | 1 |
| Momoli, F | 1 |
| Demers, L | 1 |
| Perrault, A | 1 |
| Moride, Y | 1 |
| Farlow, MR | 5 |
| Jann, MW | 2 |
| Shirley, KL | 1 |
| Small, GW | 1 |
| Nobili, F | 1 |
| Koulibaly, M | 1 |
| Vitali, P | 1 |
| Migneco, O | 1 |
| Mariani, G | 1 |
| Ebmeier, K | 1 |
| Pupi, A | 1 |
| Robert, PH | 1 |
| Rodriguez, G | 1 |
| Darcourt, J | 1 |
| Di Lazzaro, V | 2 |
| Oliviero, A | 2 |
| Tonali, PA | 2 |
| Marra, C | 2 |
| Daniele, A | 2 |
| Profice, P | 1 |
| Saturno, E | 2 |
| Pilato, F | 2 |
| Masullo, C | 1 |
| Rothwell, JC | 1 |
| Ott, BR | 1 |
| Doraiswamy, PM | 1 |
| Krishnan, KR | 1 |
| Anand, R | 11 |
| Sohn, H | 1 |
| Danyluk, J | 1 |
| Hartman, RD | 2 |
| Veach, J | 7 |
| Potki, SG | 1 |
| Hartman, R | 7 |
| Grossberg, G | 2 |
| Darreh-Shori, T | 3 |
| Almkvist, O | 3 |
| Guan, ZZ | 2 |
| Garlind, A | 1 |
| Strandberg, B | 1 |
| Svensson, AL | 1 |
| Soreq, H | 2 |
| Hellström-Lindahl, E | 3 |
| Lammich, S | 1 |
| Kaether, C | 1 |
| Capell, A | 1 |
| Zimmer, AK | 1 |
| Edbauer, D | 1 |
| Walter, J | 1 |
| Steiner, H | 1 |
| Haass, C | 1 |
| Kim, JM | 1 |
| Shin, IS | 1 |
| Yoon, JS | 1 |
| Sauer, J | 1 |
| Howard, R | 2 |
| Castro, A | 2 |
| Martinez, A | 2 |
| Dartigues, JF | 1 |
| Goulley, F | 1 |
| Bourdeix, I | 1 |
| Péré, JJ | 5 |
| Barberger-Gateau, P | 1 |
| Clegg, A | 2 |
| Bryant, J | 2 |
| Nicholson, T | 2 |
| McIntyre, L | 2 |
| De Broe, S | 2 |
| Gerard, K | 2 |
| Waugh, N | 2 |
| Zink, M | 1 |
| Sartorius, A | 1 |
| Lederbogen, F | 1 |
| Henn, FA | 1 |
| Sterling, J | 2 |
| Herzig, Y | 2 |
| Goren, T | 1 |
| Finkelstein, N | 1 |
| Lerner, D | 1 |
| Goldenberg, W | 1 |
| Miskolczi, I | 1 |
| Molnar, S | 1 |
| Rantal, F | 1 |
| Tamas, T | 1 |
| Toth, G | 1 |
| Zagyva, A | 1 |
| Zekany, A | 1 |
| Finberg, J | 1 |
| Lavian, G | 1 |
| Gross, A | 1 |
| Friedman, R | 1 |
| Razin, M | 1 |
| Huang, W | 1 |
| Krais, B | 1 |
| Chorev, M | 1 |
| Youdim, MB | 2 |
| Rombouts, SA | 1 |
| Barkhof, F | 1 |
| Van Meel, CS | 1 |
| Scheltens, P | 2 |
| McRae, TD | 1 |
| Schwam, EM | 1 |
| Kaasinen, V | 1 |
| Någren, K | 1 |
| Järvenpää, T | 1 |
| Roivainen, A | 1 |
| Yu, M | 2 |
| Oikonen, V | 1 |
| Kurki, T | 1 |
| Rinne, JO | 1 |
| Casademont, J | 1 |
| Miró, O | 1 |
| Rodriguez-Santiago, B | 1 |
| Viedma, P | 1 |
| Blesa, R | 1 |
| Cardellach, F | 1 |
| Nabeshima, T | 1 |
| Noda, Y | 1 |
| Kamei, H | 1 |
| Erkinjuntti, T | 2 |
| Skoog, I | 2 |
| Lane, R | 3 |
| Andrews, C | 2 |
| Rigaud, AS | 2 |
| André, G | 2 |
| Vellas, B | 4 |
| Touchon, J | 2 |
| Parnetti, L | 2 |
| Amici, S | 2 |
| Lanari, A | 2 |
| Romani, C | 1 |
| Antognelli, C | 2 |
| Andreasen, N | 1 |
| Minthon, L | 1 |
| Davidsson, P | 1 |
| Pottel, H | 1 |
| Blennow, K | 2 |
| Gallai, V | 2 |
| Stefanova, E | 2 |
| Huizing, AR | 1 |
| Berghmans, RL | 1 |
| Widdershoven, GA | 1 |
| Verhey, FR | 1 |
| Kohler, J | 1 |
| Riepe, MW | 1 |
| Jendroska, K | 1 |
| Pilartz, H | 1 |
| Adler, G | 4 |
| Berger, FM | 1 |
| Calabrese, P | 1 |
| Frölich, L | 1 |
| Gertz, HJ | 1 |
| Hampel, H | 2 |
| Haupt, M | 1 |
| Mielke, R | 1 |
| Paulus, HJ | 1 |
| Zedlick, D | 1 |
| Farlow, M | 3 |
| Wobrock, T | 1 |
| Retz-Junginger, P | 1 |
| Retz, W | 1 |
| Supprian, T | 1 |
| Rösler, M | 2 |
| Thacker, PD | 1 |
| Gabelli, C | 1 |
| Borroni, B | 1 |
| Pettenati, C | 1 |
| Bordonali, T | 1 |
| Akkawi, N | 1 |
| Di Luca, M | 1 |
| Padovani, A | 1 |
| Gibson, RC | 1 |
| Barnaby, L | 1 |
| Lewis, HD | 1 |
| Pérez Revuelta, BI | 1 |
| Nadin, A | 1 |
| Neduvelil, JG | 1 |
| Harrison, T | 1 |
| Pollack, SJ | 1 |
| Shearman, MS | 1 |
| Potkin, S | 1 |
| Koumaras, B | 1 |
| Mirski, D | 2 |
| Bianchetti, A | 1 |
| Rozzini, R | 1 |
| Trabucchi, M | 1 |
| Amit, T | 1 |
| Bar-Am, O | 1 |
| Yogev-Falach, M | 1 |
| Williams, BR | 1 |
| Nazarians, A | 1 |
| Gill, MA | 1 |
| Alagiakrishnan, K | 1 |
| Sclater, A | 1 |
| Robertson, D | 1 |
| Doody, RS | 1 |
| Warner, J | 1 |
| Butler, R | 1 |
| Prabhakaran, P | 1 |
| Abe, Y | 1 |
| Aoyagi, A | 1 |
| Hara, T | 1 |
| Abe, K | 1 |
| Yamazaki, R | 1 |
| Kumagae, Y | 1 |
| Naruto, S | 1 |
| Koyama, K | 1 |
| Marumoto, S | 1 |
| Tago, K | 1 |
| Toda, N | 1 |
| Takami, K | 1 |
| Yamada, N | 1 |
| Ori, M | 1 |
| Kogen, H | 1 |
| Kaneko, T | 1 |
| Rakonczay, Z | 1 |
| Fuchsberger, T | 1 |
| Möller, HJ | 1 |
| Baezner, H | 1 |
| Daffertshofer, M | 1 |
| Lojkowska, W | 1 |
| Ryglewicz, D | 1 |
| Jedrzejczak, T | 1 |
| Minc, S | 1 |
| Jakubowska, T | 1 |
| Jarosz, H | 1 |
| Bochynska, A | 1 |
| Johnson, A | 1 |
| Loria-Kanza, Y | 2 |
| Alhainen, K | 1 |
| Brassen, S | 3 |
| Kaufer, DI | 1 |
| Gauthier, S | 3 |
| Emre, M | 1 |
| Bullock, R | 4 |
| Grossberg, GT | 2 |
| Potkin, SG | 2 |
| Auriacombe, S | 2 |
| Chwalek, K | 1 |
| Dieter, B | 1 |
| Teufel, M | 1 |
| Ibach, B | 1 |
| Haen, E | 1 |
| Alisky, JM | 1 |
| Li, YM | 4 |
| Marin, D | 1 |
| Amaya, K | 1 |
| Casciano, R | 1 |
| Puder, KL | 1 |
| Casciano, J | 1 |
| Chang, S | 1 |
| Snyder, EH | 2 |
| Cheng, I | 1 |
| Cuccia, AJ | 1 |
| Flores-Flores, C | 1 |
| Dileone, M | 1 |
| Ghirlanda, S | 1 |
| Gainotti, G | 1 |
| Burns, A | 2 |
| Quarg, P | 1 |
| Feldman, H | 2 |
| Scarpini, E | 1 |
| Hermann, N | 1 |
| Mesenbrink, P | 1 |
| Mancione, L | 2 |
| Tekin, S | 1 |
| Ferris, S | 1 |
| Suh, DC | 1 |
| Arcona, S | 1 |
| Thomas, SK | 1 |
| Powers, C | 1 |
| Rabinowicz, AL | 1 |
| Shin, H | 1 |
| Rioux, S | 1 |
| Liang, YQ | 1 |
| Tang, XC | 1 |
| Baki, L | 1 |
| Shioi, J | 1 |
| Wen, P | 1 |
| Shao, Z | 1 |
| Schwarzman, A | 1 |
| Gama-Sosa, M | 1 |
| Neve, R | 1 |
| Robakis, NK | 1 |
| Mossello, E | 1 |
| Tonon, E | 1 |
| Caleri, V | 1 |
| Tilli, S | 1 |
| Cantini, C | 1 |
| Cavallini, MC | 1 |
| Bencini, F | 1 |
| Mecacci, R | 1 |
| Marini, M | 1 |
| Bardelli, F | 1 |
| Sarcone, E | 1 |
| Razzi, E | 1 |
| Biagini, CA | 1 |
| Masotti, G | 1 |
| Prasher, VP | 1 |
| Voisin, T | 1 |
| Reynish, E | 1 |
| Portet, F | 1 |
| Evans, JG | 1 |
| Wilcock, G | 1 |
| Birks, J | 3 |
| van Dyck, CH | 1 |
| Finkel, SI | 1 |
| Chun, J | 1 |
| Yin, YI | 1 |
| Yang, G | 1 |
| Tarassishin, L | 1 |
| Bartolucci, C | 1 |
| Siotto, M | 1 |
| Ghidini, E | 1 |
| Amari, G | 1 |
| Bolzoni, PT | 1 |
| Racchi, M | 1 |
| Villetti, G | 2 |
| Delcanale, M | 1 |
| Lamba, D | 1 |
| Freskos, JN | 1 |
| Fobian, YM | 1 |
| Benson, TE | 1 |
| Moon, JB | 1 |
| Bienkowski, MJ | 1 |
| Brown, DL | 1 |
| Emmons, TL | 1 |
| Heintz, R | 1 |
| Laborde, A | 1 |
| McDonald, JJ | 1 |
| Mischke, BV | 1 |
| Molyneaux, JM | 1 |
| Mullins, PB | 1 |
| Bryan Prince, D | 1 |
| Paddock, DJ | 1 |
| Tomasselli, AG | 1 |
| Winterrowd, G | 1 |
| Groner, E | 1 |
| Ashani, Y | 1 |
| Schorer-Apelbaum, D | 1 |
| Guo, T | 1 |
| Gu, H | 1 |
| Hobbs, DW | 1 |
| Rokosz, LL | 1 |
| Stauffer, TM | 1 |
| Jacob, B | 1 |
| Clader, JW | 1 |
| Lahiri, DK | 1 |
| Alley, GM | 1 |
| Tweedie, D | 1 |
| Chen, D | 1 |
| Greig, NH | 1 |
| Zhao, B | 1 |
| Neitzel, M | 1 |
| Marugg, J | 1 |
| Jagodzinski, J | 1 |
| Lee, M | 1 |
| Hu, K | 1 |
| Schenk, D | 1 |
| Yednock, T | 1 |
| Basi, G | 1 |
| Sharples, RA | 1 |
| Vella, LJ | 1 |
| Nisbet, RM | 1 |
| Naylor, R | 1 |
| Perez, K | 1 |
| Barnham, KJ | 1 |
| Masters, CL | 1 |
| Hill, AF | 1 |
| Bergstrom, CP | 1 |
| Sloan, CP | 1 |
| Lau, WY | 1 |
| Smith, DW | 1 |
| Zheng, M | 1 |
| Hansel, SB | 1 |
| Polson, CT | 1 |
| Corsa, JA | 1 |
| Barten, DM | 1 |
| Felsenstein, KM | 1 |
| Roberts, SB | 1 |
| Borroni, E | 1 |
| Damsma, G | 1 |
| Giovacchini, C | 1 |
| Mutel, V | 1 |
| Jakob-Rötne, R | 1 |
| Da Prada, M | 1 |
| Amstutz, R | 1 |
| Boddeke, H | 2 |
| Gmelin, G | 1 |
| Malanowski, J | 1 |
| Sramek, JJ | 3 |
| Wardle, TS | 1 |
| Irwin, P | 1 |
| Palacios, JM | 1 |
| Smith, CP | 1 |
| Bores, GM | 1 |
| Petko, W | 1 |
| Li, M | 1 |
| Selk, DE | 1 |
| Rush, DK | 1 |
| Camacho, F | 1 |
| Winslow, JT | 1 |
| Fishkin, R | 1 |
| Cunningham, DM | 1 |
| Brooks, KM | 1 |
| Roehr, J | 1 |
| Hartman, HB | 1 |
| Davis, L | 1 |
| Vargas, HM | 1 |
| Schneider, LS | 2 |
| Honma, A | 1 |
| Polinsky, RJ | 2 |
| Jhee, SS | 3 |
| Hourani, J | 1 |
| Zolnouni, P | 1 |
| Spencer, CM | 1 |
| Noble, S | 1 |
| Lacomblez, L | 1 |
| Derquesné, C | 1 |
| Olde Rikkert, MG | 1 |
| Jansen, RW | 1 |
| Cicin-Sain, A | 1 |
| Agid, Y | 1 |
| Dal-Bianco, P | 1 |
| Stähelin, HB | 2 |
| Gharabawi, M | 1 |
| Bayer, T | 1 |
| Berger, A | 1 |
| Forette, F | 1 |
| Gharabawi, G | 1 |
| Lemière, J | 1 |
| Van Gool, D | 1 |
| Dom, R | 1 |
| Bentham, P | 1 |
| Gray, R | 1 |
| Sellwood, E | 1 |
| Raftery, J | 1 |
| Vermeulen, M | 1 |
| de Haan, RJ | 1 |
| Selai, CE | 1 |
| Trimble, MR | 1 |
| Rossor, MN | 1 |
| Harvey, RJ | 1 |
| Storosum, JG | 1 |
| van Zwieten-Boot, BJ | 1 |
| Elferink, AJ | 1 |
| Hébert, M | 1 |
| Kennedy, JS | 1 |
| Johnson, B | 1 |
| Loosen, P | 1 |
| Laplanche, R | 1 |
| Schmidt, D | 1 |
| Mancione, LC | 1 |
| Parris, WC | 1 |
| Ebert, MH | 1 |
| McMillan, H | 1 |
| Russell, E | 1 |
| Page, S | 1 |
| Sim, A | 1 |
| Passmore, P | 1 |
| Wilkinson, D | 1 |
| Jones, R | 1 |
| Kosasa, T | 2 |
| Kuriya, Y | 2 |
| Matsui, K | 1 |
| Yamanishi, Y | 2 |
| Messina, JC | 1 |
| Iakovidou, V | 2 |
| Tsolaki, M | 2 |
| Lai, MT | 1 |
| Xu, M | 1 |
| Huang, Q | 1 |
| DiMuzio-Mower, J | 1 |
| Sardana, MK | 1 |
| Shi, XP | 1 |
| Yin, KC | 1 |
| Shafer, JA | 1 |
| Gardell, SJ | 1 |
| Kumar, V | 1 |
| Messina, J | 4 |
| Hauber, AB | 2 |
| Gnanasakthy, A | 2 |
| Mauskopf, JA | 2 |
| Trabace, L | 3 |
| Cassano, T | 3 |
| Steardo, L | 3 |
| Pietra, C | 2 |
| Kendrick, KM | 2 |
| Cuomo, V | 3 |
| Kwak, YT | 1 |
| Han, IW | 1 |
| Baik, J | 1 |
| Koo, MS | 1 |
| Bala, MV | 1 |
| Richter, A | 1 |
| Babic, T | 1 |
| Banfic, L | 1 |
| Papa, J | 1 |
| Barisic, N | 1 |
| Jelincic, Z | 1 |
| Zurak, N | 1 |
| Stahl, SM | 2 |
| Grace, JB | 1 |
| Walker, MP | 1 |
| McKeith, IG | 1 |
| Fisher, A | 1 |
| Bertonati, C | 1 |
| Marta, M | 1 |
| Patamia, M | 1 |
| Colella, A | 1 |
| Pomponi, M | 1 |
| Cummings, JL | 2 |
| Baladi, JF | 1 |
| Bailey, PA | 1 |
| Black, S | 1 |
| Bouchard, RW | 1 |
| Farcnik, KD | 1 |
| Kertesz, A | 1 |
| Mohr, E | 1 |
| Robillard, A | 1 |
| Grutzendler, J | 1 |
| Morris, JC | 1 |
| Linkins, KW | 1 |
| Lloyd, JR | 1 |
| Hjelmstad, GO | 1 |
| Strausbaugh, HJ | 1 |
| Patterson, C | 1 |
| Hogan, DB | 1 |
| Hake, A | 1 |
| Ogura, H | 1 |
| Richard, E | 2 |
| Lemstra, AW | 1 |
| Walstra, GJ | 2 |
| van Gool, WA | 2 |
| Lamb, HM | 1 |
| Goa, KL | 1 |
| Martys-Zage, JL | 1 |
| Kim, SH | 1 |
| Berechid, B | 1 |
| Bingham, SJ | 1 |
| Chu, S | 1 |
| Sklar, J | 1 |
| Nye, J | 1 |
| Sisodia, SS | 1 |
| Hake, AM | 1 |
| Cagiano, R | 1 |
| Tattoli, M | 1 |
| Lampley-Dallas, VT | 1 |
| Gavrilova, SI | 1 |
| Zharikov, GA | 1 |
| Deleu, D | 1 |
| Slagle, MA | 1 |
| Smith, DJ | 1 |
| Yukhnevich, S | 1 |
| Gobburu, JV | 1 |
| Tammara, V | 1 |
| Lesko, L | 1 |
| Yuan, R | 1 |
| Romani, R | 1 |
| Fleming, K | 1 |
| Alva, G | 1 |
| Keator, D | 1 |
| Carreon, D | 1 |
| Wu, JC | 1 |
| Fallon, JH | 1 |
| Winblad, B | 1 |
| Ventura, M | 1 |
| Sternon, J | 1 |
| Monastero, R | 1 |
| Lopez, G | 1 |
| Mannino, M | 1 |
| Camarda, R | 1 |
| Caffarra, P | 1 |
| Majer, S | 1 |
| Godani, M | 1 |
| Paolello, P | 1 |
| Catinella, S | 1 |
| Pelizzi, N | 1 |
| Puccini, P | 1 |
| Marchetti, S | 1 |
| Zanol, M | 1 |
| Acerbi, D | 1 |
| Ventura, P | 1 |
| Schreiter Gasser, U | 1 |
| Gasser, T | 2 |
| van Campen, J | 1 |
| Vissers, E | 1 |
| Ballard, CG | 1 |
| Gasser, US | 1 |
| Figueroa, DJ | 1 |
| Morris, JA | 1 |
| Kandpal, G | 1 |
| Chen, E | 1 |
| Austin, CP | 1 |
| Mustazza, C | 1 |
| Borioni, A | 1 |
| Del Giudice, MR | 1 |
| Gatta, F | 1 |
| Ferretti, R | 1 |
| Meneguz, A | 1 |
| Volpe, MT | 1 |
| Lorenzini, P | 1 |
| Bilikiewicz, A | 1 |
| Opala, G | 1 |
| Podemski, R | 1 |
| Puzyński, S | 1 |
| Łapin, J | 1 |
| Sołtys, K | 1 |
| Ochudło, S | 1 |
| Barcikowska, M | 1 |
| Pfeffer, A | 1 |
| Bilińska, M | 1 |
| Paradowski, B | 1 |
| Parnowski, T | 1 |
| Gabryelewicz, T | 1 |
| Schmidt, R | 1 |
| Lechner, A | 1 |
| Petrovic, K | 1 |
| Schölzel-Dorenbos, CJ | 1 |
| Connolly, C | 1 |
| Venneri, A | 1 |
| Shanks, MF | 1 |
| Staff, RT | 1 |
| Pestell, SJ | 1 |
| Forbes, KE | 1 |
| Gemmell, HG | 1 |
| Murray, AD | 1 |
| Hossain, M | 1 |
| Shiovitz, T | 1 |
| McDonald, C | 1 |
| Sedek, G | 1 |
| Pommier, F | 1 |
| Allain, H | 1 |
| Tribut, O | 1 |
| Reymann, JM | 1 |
| Polard, E | 1 |
| Lecavorzin, P | 1 |
| Bentue-Ferrer, D | 1 |
| Heinze, M | 1 |
| Andreae, D | 1 |
| Grohmann, R | 1 |
| Bottino, CM | 1 |
| Carvalho, IA | 1 |
| Alvarez, AM | 1 |
| Avila, R | 1 |
| Zukauskas, PR | 1 |
| Bustamante, SE | 1 |
| Andrade, FC | 1 |
| Hototian, SR | 1 |
| Saffi, F | 1 |
| Camargo, CH | 1 |
| Walsh, E | 1 |
| Dourish, J | 1 |
| Werber, AE | 1 |
| Klein, C | 1 |
| Rabey, JM | 1 |
| Morganroth, J | 1 |
| Graham, S | 1 |
| Loverre, A | 1 |
| Frank, JC | 1 |
| Cherry, D | 1 |
| Kohatsu, ND | 1 |
| Kemp, B | 1 |
| Hewett, L | 1 |
| Mittman, B | 1 |
| Robert, P | 1 |
| Blount, PJ | 1 |
| Nguyen, CD | 1 |
| McDeavitt, JT | 1 |
| Gray, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease[NCT03082755] | Phase 4 | 156 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| Differences of Functional Changes in Brain by Rivastigmine According to Butyrylcholinesterase Alleles in Alzheimer's Disease Patients(Rivastigmine, Imaging, and BuChE in AD: RIBA)[NCT02063269] | 70 participants (Anticipated) | Interventional | 2014-02-28 | Active, not recruiting | |||
| Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects[NCT00954252] | Phase 1 | 84 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
60 reviews available for carbamates and Alzheimer Disease
| Article | Year |
|---|---|
Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Ligands | 2022 |
Computational Studies on Acetylcholinesterase Inhibitors: From Biochemistry to Chemistry.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Carbamates; Cholinesterase Inhibitors; Human | 2020 |
Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Topics: Aged; Alzheimer Disease; Canada; Carbamates; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donep | 2002 |
Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Humans; Nootropic Age | 2002 |
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Topics: Aging; Alzheimer Disease; Biological Availability; Carbamates; Cholinesterase Inhibitors; Donepezil; | 2002 |
Medical treatment of Alzheimer's disease: past, present, and future.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials a | 2002 |
Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Binding Sites; Carbamates; Cholinesterase Inhibitors; | 2001 |
Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cost of Illness; Cost-Benefit Analys | 2002 |
Ganstigmine (CHF 2819).
Topics: Acetylcholine; Adult; Alkaloids; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; | 2002 |
[Anti-dementia drugs for Alzheimer disease in present and future].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Cholinesterase Inhibitors; Done | 2002 |
A clinical overview of cholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; | 2002 |
Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cognition; Disease Progression; Economics | 2003 |
A review of rivastigmine: a reversible cholinesterase inhibitor.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Drug | 2003 |
Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Topics: Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Clinical Trials as To | 2003 |
Dementia.
Topics: Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Carbamates; Donepezil; Galantamine; Ginkgo | 2003 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Cli | 2003 |
[Subcortical vascular encephalopathy].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amantadine; Brain; Carbamates; Clinical Trials as Topic; | 2003 |
Update on rivastigmine.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivasti | 2003 |
Ganstigmine. Chiesi.
Topics: Alkaloids; Alzheimer Disease; Animals; Carbamates; Clinical Trials as Topic; Drugs, Investigational; | 2003 |
[Mechanisms of action of Alzheimer medications].
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Cognition; Donepezil; Excitatory | 2003 |
Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Femal | 2003 |
Acetylcholinesterase inhibition in Alzheimer's Disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galan | 2004 |
Gamma-secretase: a catalyst of Alzheimer disease and signal transduction.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; As | 2001 |
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Galantamine; Hum | 2004 |
What are the treatment options for patients with severe Alzheimer's disease?
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Galantamine; Hum | 2004 |
Evidence-based pharmacotherapy of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cost-Benefit Ana | 2004 |
Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Mental D | 2004 |
Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Carb | 2006 |
Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Carbamates; Cats; Chol | 1993 |
New therapeutic approaches to Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cognitio | 1996 |
[Therapeutic agents for Alzheimer's disease].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Human | 1998 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; D | 1998 |
Rivastigmine. A review of its use in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug In | 1998 |
Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.
Topics: Acetylcholine; Alzheimer Disease; Animals; Carbamates; Chemical and Drug Induced Liver Injury; Choli | 1999 |
[New therapies in neurology, but who benefits?].
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antiviral Agents; Carbamates; Humans; Interferon-b | 1999 |
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; | 2000 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbama | 2000 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Phenylcarb | 2000 |
Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Cost Savings; Economics, Pharmaceutical; Female; Health Care Co | 2000 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbama | 2000 |
Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Carbamates; Cheirogaleidae; Disease Mo | 2000 |
Cholinesterase inhibitors stabilize Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition | 2000 |
Cholinesterase inhibitors for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cost-Benefit Ana | 2001 |
Brief review: rivastigmine, a second cholinesterase inhibitor.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Lewy Body Disease; Neuroprot | 2001 |
[Evaluation of the therapeutic effects in individual patients with Alzheimer disease].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cognition; Humans; Netherlands; Nootropic | 2001 |
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Topics: Alzheimer Disease; Carbamates; Cost-Benefit Analysis; Donepezil; Galantamine; Humans; Indans; Neurop | 2001 |
Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition; Hea | 2001 |
Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Interaction | 2001 |
Use of cholinesterase inhibitors for treatment of Alzheimer disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Ph | 2001 |
[Current strategies of pathogenetic therapy of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Carbamates; Cholinesterase Inhibitors; Clinic | 2001 |
[Anticholinesterase agents in Alzheimer's disease].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carbamates; Cholinesterase | 2001 |
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Double | 2001 |
Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitor | 2002 |
Understanding changes in cholinergic function: implications for treating dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinergic Fibers; Cholinesterase Inhibi | 2002 |
[Perspectives for drug treatment in Alzheimer's disease].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Gala | 2001 |
The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Dementia; Hum | 2002 |
CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor.
Topics: Acetylcholine; Alzheimer Disease; Amino Acids; Animals; Biogenic Monoamines; Carbamates; Cholinester | 2002 |
Guidelines for managing Alzheimer's disease: Part II. Treatment.
Topics: Advance Directives; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; D | 2002 |
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therap | 2002 |
Clinical use of cholinomimetic agents: a review.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Brain Injuries; Carbamates; Clinical Trials as | 2002 |
43 trials available for carbamates and Alzheimer Disease
| Article | Year |
|---|---|
Nighttime Agitation and Restless Legs Syndrome in Persons With Alzheimer's Disease: Study Protocol for a Double-Blind, Placebo-Controlled, Randomized Trial (NightRest).
Topics: Aged; Alzheimer Disease; Anxiety; Carbamates; Double-Blind Method; Female; gamma-Aminobutyric Acid; | 2020 |
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Butyrylcholinesterase; Carbamates; | 2002 |
Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Carbamates; Double-Blind Method; F | 2002 |
Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; | 2002 |
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Attention; Butyrylcholinesterase; Carbamates; Choline | 2002 |
Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; M | 2002 |
[Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorde | 2002 |
Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Carbamates; Cerebral Cortex; Cholinesterase Inhibitor | 2002 |
Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Electron Transport; Female; Humans; | 2003 |
Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; | 2002 |
No additional benefit of HRT on response to rivastigmine in menopausal women with AD.
Topics: Activities of Daily Living; Administration, Cutaneous; Administration, Oral; Aged; Alzheimer Disease | 2003 |
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Butyrylcholinesterase; C | 2002 |
Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E2; Apolipoprotein E4; Apolipoprotein | 2003 |
Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Carbamates; Cholesterol; Cholinesterase Inhibitors; Dise | 2003 |
Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition; | 2003 |
Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors.
Topics: Acetylcarnitine; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug The | 2003 |
The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.
Topics: Acetylcholine; Aged; Alzheimer Disease; Auditory Perception; Carbamates; Cerebrovascular Circulation | 2003 |
[Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Combined Modality Therapy; Double-Blind Meth | 2003 |
Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Electr | 2003 |
Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Female; Humans; | 2003 |
Prediction of treatment response to rivastigmine in Alzheimer's dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Cognition | 2004 |
Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Attention; Carbamates; Case-Control Studies; Chi-Square | 2004 |
Behavioral symptoms in mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibito | 2004 |
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Fema | 2004 |
Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dose-Response Rel | 1996 |
Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Carbamates; Cere | 1998 |
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase I | 1999 |
A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Double-Blind Method; Electrocardiogr | 1999 |
Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Mental Status Schedule; Neuroprote | 1999 |
An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dementia, Vascula | 2000 |
Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
Topics: Aged; Algorithms; Alzheimer Disease; Canada; Carbamates; Cholinesterase Inhibitors; Cognition; Cost | 2000 |
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
Topics: Age Factors; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition; Disease Prog | 2000 |
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progressi | 2001 |
Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Electroencephalography; Female; Huma | 2001 |
Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans | 2001 |
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Chemistry; Carbamates; Double-Blind Method; | 2001 |
An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Disease Progression; Female; Humans; Male; N | 2002 |
Rivastigmine in outpatient services: experience of 114 neurologists in Austria.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Austria; Carbamates; Cognition; Disease Progression; Fem | 2002 |
Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cluster | 2002 |
Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Biological Avail | 2002 |
Electrocardiographic effects of rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bradycardia; Carbamates; Cardiovascular System; Cholines | 2002 |
Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female | 2002 |
Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Humans; Male; Phenylcarbamates; P | 1991 |
138 other studies available for carbamates and Alzheimer Disease
| Article | Year |
|---|---|
Neuroprotective effects of some epigenetic modifying drugs' on Chlamydia pneumoniae-induced neuroinflammation: A novel model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Chlamydophila Infections; Chlamydophila pneumo | 2021 |
Design, synthesis, and biological evaluation of carbamate derivatives of N-salicyloyl tryptamine as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain | 2022 |
Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholin | 2022 |
Photoswitchable Pseudoirreversible Butyrylcholinesterase Inhibitors Allow Optical Control of Inhibition
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Azo Compounds; Butyrylcholinesterase; Carbamates; | 2022 |
Design, synthesis and evaluation of novel scutellarin and scutellarein-N,N-bis-substituted carbamate-l-amino acid derivatives as potential multifunctional therapeutics for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amino Acids; Amyloid beta-Peptides; Animals; Antioxidants; | 2022 |
Carbamate-based N-Substituted tryptamine derivatives as novel pleiotropic molecules for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Neuroprotect | 2022 |
Discovery of carbamate-based N-salicyloyl tryptamine derivatives as novel pleiotropic agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Cholinesterase Inhibitor | 2022 |
Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Disease Mo | 2019 |
Design, synthesis and evaluation of diosgenin carbamate derivatives as multitarget anti-Alzheimer's disease agents.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; A | 2020 |
Tert-butyl-(4-hydroxy-3-((3-(2-methylpiperidin-yl)propyl)carbamoyl)phenyl)carbamate Has Moderated Protective Activity in Astrocytes Stimulated with Amyloid Beta 1-42 and in a Scopolamine Model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Carbamates; Disease Models, Animal; H | 2020 |
In silico Screening of Pyridoxine Carbamates for Anti-Alzheimer's Activities.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Computer Si | 2021 |
Synthesis and Initial Characterization of a Selective, Pseudo-irreversible Inhibitor of Human Butyrylcholinesterase as PET Tracer.
Topics: Alzheimer Disease; Animals; Brain; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Dru | 2021 |
Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes/Macrophages from Alzheimer's Disease Patients.
Topics: Aged; Alzheimer Disease; Amidohydrolases; Benzamides; Carbamates; Female; Humans; Interleukin-6; Leu | 2021 |
Hybridization-based design of novel anticholinesterase indanone-carbamates for Alzheimer's disease: Synthesis, biological evaluation, and docking studies.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Carbamates; Chemistry, Phar | 2021 |
New Coumarin Derivatives as Cholinergic and Cannabinoid System Modulators.
Topics: Alzheimer Disease; Amidohydrolases; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cannabinoid | 2021 |
Fatty Acid Amide Hydrolase (FAAH) Inhibition Modulates Amyloid-Beta-Induced Microglia Polarization.
Topics: Alzheimer Disease; Amidohydrolases; Amyloid beta-Peptides; Animals; Arachidonic Acids; Benzamides; C | 2021 |
Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholine | 2021 |
Design, synthesis and biological evaluation of naringenin carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Carb | 2021 |
Chalcone-based carbamates for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Carbamates; Cell Line, Tumor; Cell Survival; Chalcone; Cholinesterase Inhibitors; | 2017 |
Semagacestat Is a Pseudo-Inhibitor of γ-Secretase.
Topics: Alanine; Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; An | 2017 |
Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Humans; Ligan | 2019 |
Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: modulation by cannabinoid agonists.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amidohydrolases; Amyloid beta-Peptides; Animals; | 2014 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyr | 2015 |
Design, synthesis, and biological evaluation of scutellarein carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Brain; Butyrylcholinestera | 2015 |
Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic α7 Nicotinic Receptor Drugs.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocyt | 2015 |
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amidohydrolases; Butyrylcholinesterase; Carbamates; Cell Li | 2016 |
Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Butyrylcholinesterase; Carbamates; Cell Line; Cholinestera | 2016 |
A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Ac | 2010 |
Dimethyl-carbamic acid 2,3-Bis-Dimethylcarbamoyloxy-6-(4-Ethyl-Piperazine-1-Carbonyl)-phenyl ester: a novel multi-target therapeutic approach to neuroprotection.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Brain; Carbam | 2010 |
Functional interactions of fibrillar and oligomeric amyloid-β with alpha7 nicotinic receptors in Alzheimer's disease.
Topics: Aged; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Analysis of | 2011 |
Characterization of a Drosophila Alzheimer's disease model: pharmacological rescue of cognitive defects.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Be | 2011 |
Abnormal cross-talk between mutant presenilin 1 (I143T, G384A) and glycosphingolipid biosynthesis.
Topics: Alzheimer Disease; Amino Acid Substitution; Amyloid Precursor Protein Secretases; Animals; Base Sequ | 2012 |
C-terminal fragment of N-cadherin accelerates synapse destabilization by amyloid-β.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secreta | 2012 |
The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-β and in the cortex of aged rats.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Arac | 2012 |
Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Dose-Respon | 2012 |
Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Apoptosis; Carbamates; Chickens; Cholinesterase Inhibitors | 2012 |
Critical role of presenilin-dependent γ-secretase activity in DNA damage-induced promyelocytic leukemia protein expression and apoptosis.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Apoptosis; Brain; Camptothecin; Ca | 2013 |
Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Brain; Carbamates; Case-Control Studies; Cerebrovascular Circulation; Choli | 2002 |
Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinergic Fibers; Cholinesterase Inhibitors; Electric Stimula | 2002 |
Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amylo | 2002 |
The impact of journal advertisements on prescribers of cholinesterase inhibitors.
Topics: Advertising; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Prescriptions | 2002 |
Electroconvulsive therapy in a patient receiving rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Depressive Disord | 2002 |
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Carbamates; | 2002 |
Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Attention; Brain Mapping; Carbamates; Cerebral Cortex; Cholinergic Fibers; | 2002 |
Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Donepezil; Female; Humans; Indans; Male; Mid | 2002 |
[Ethical aspects of anti-Alzheimer drugs: experiences of caregivers].
Topics: Aged; Alzheimer Disease; Carbamates; Caregivers; Cholinesterase Inhibitors; Cognition; Decision Maki | 2002 |
[Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].
Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Carbamates; Cholinesterase Inhibitors; Dihy | 2002 |
[Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
Topics: Affective Disorders, Psychotic; Aged; Aged, 80 and over; Alzheimer Disease; Anxiety Disorders; Carba | 2003 |
Surprising discovery with Alzheimer's medication.
Topics: Acetylcholine; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Crystallography, X | 2003 |
Rivastigmine in the treatment of alcohol-induced persisting dementia.
Topics: Alcohol-Induced Disorders, Nervous System; Alzheimer Disease; Carbamates; Central Nervous System Dep | 2003 |
Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Aspartic Ac | 2003 |
Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Carbamates; Cell Line; Enzyme Activation | 2003 |
Role of cholinesterase inhibitor in the management of sexual aggression in an elderly demented woman.
Topics: Aged; Aggression; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dementia, Vascular; Fema | 2003 |
Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Administration, Oral; Aging; Alzheimer Disease; Animals; Carbamates; Carrier P | 2003 |
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cer | 2003 |
Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Brain; Carbamates; Cholinesterase Inhibitors; Diagnos | 2004 |
No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.
Topics: Aged; Alzheimer Disease; Carbamates; Donepezil; Female; Humans; Indans; Male; Neuroprotective Agents | 2003 |
A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Inda | 2003 |
Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; France; Galantam | 2003 |
Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Caregivers; Cholinesterase Inhibitors; Co | 2003 |
Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Topics: Acetylcholinesterase; Aged; Alternative Splicing; Alzheimer Disease; Blotting, Western; Carbamates; | 2004 |
Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease.
Topics: Afferent Pathways; Aged; Alzheimer Disease; Carbamates; Cerebral Cortex; Cholinergic Fibers; Choline | 2004 |
Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; M | 2004 |
Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Carbamates; Cholinesterase Inhibit | 2004 |
[Acetylcholinesterase inhibitors].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Galantamine; Humans; Phenylcarbamates; Riv | 2003 |
Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.
Topics: Acetylcholine; Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Brain Chemistry; Carbama | 2004 |
PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations.
Topics: Alzheimer Disease; Animals; Apoptosis; Blotting, Western; Cadherins; Carbamates; Cell Line, Transfor | 2004 |
Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Top | 2004 |
Stereoselective synthesis of photoreactive peptidomimetic gamma-secretase inhibitors.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Carbamates; C | 2004 |
Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819).
Topics: Acetylcholinesterase; Administration, Oral; Alkaloids; Alzheimer Disease; Animals; Binding Sites; Br | 2006 |
Design of potent inhibitors of human beta-secretase. Part 2.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Carbamates; Cells, Cultured; Drug Design; H | 2007 |
The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Humans; Indans; Inhibiti | 2007 |
Design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as gamma-secretase inhibitors.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Carbamates; Drug Design; Enzyme Inhibitors; | 2007 |
Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Buty | 2007 |
Identification of gamma-secretase inhibitor potency determinants on presenilin.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; | 2008 |
Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2008 |
Carbamate-appended N-alkylsulfonamides as inhibitors of gamma-secretase.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Brain; Carb | 2008 |
A novel acetylcholinesterase inhibitor, Ro 46-5934, which interacts with muscarinic M2 receptors.
Topics: Acetylcholine; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Corpus Striatum; E | 1994 |
Alzheimer's disease: new pharmacological perspectives.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dihydropyridines; Donepezil; Humans; Indan | 1996 |
Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.
Topics: Acetylcholinesterase; Administration, Oral; Alzheimer Disease; Aminopyridines; Animals; Avoidance Le | 1997 |
[Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
Topics: Acetylcholinesterase; Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Humans; Neuro | 1998 |
[Drug therapy strategies in Alzheimer's disease].
Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Car | 1998 |
[New perspectives for Alzheimer patients: acetylcholine inhibition with Rivastigmine. Congress of the European Neurologic Society. Nice, 6 July 199].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 1998 |
[Alzheimer's disease. Foreword].
Topics: Age Factors; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Humans; Inda | 1998 |
[Cholinesterase inhibitors in Alzheimer disease: preliminary recommendations for treatment].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Drug Approval; Eu | 1998 |
Commentary: Another piece of the Alzheimer's jigsaw.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 1999 |
Science commentary: rational drug design for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 1999 |
Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Tr | 1999 |
Effectiveness of rivastigmine in Alzheimer's disease. Patients' view on quality of life should be assessed.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Quality of Life; | 1999 |
Effectiveness of rivastigmine in Alzheimer's disease. Guidelines do not ignore clinically relevant end points.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Practice Guideli | 1999 |
[Alzheimer disease: efficacy and tolerance of rivastagmine].
Topics: Aged; Alzheimer Disease; Carbamates; Double-Blind Method; Humans; Multicenter Studies as Topic; Neur | 1999 |
Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
Topics: Acetylcholinesterase; Adolescent; Adult; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Choli | 1999 |
New drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Donepezil; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperi | 1999 |
Rivastigmine: a review.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Tr | 1999 |
Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.
Topics: Alzheimer Disease; Carbamates; Clinical Trials as Topic; Humans; Neuroprotective Agents; Patient Sel | 2000 |
Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
Topics: Administration, Oral; Alzheimer Disease; Animals; Benzazepines; Brain; Carbamates; Cholinesterase In | 2000 |
Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Comorbidity; Cytochrome P-450 Enzyme | 2000 |
Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Aspartic Ac | 2000 |
New insights into genetics and pathophysiology of Alzheimer's disease: what are the clinical and therapeutic implications?
Topics: Acetylcholinesterase; Alzheimer Disease; Brain; Butyrylcholinesterase; Carbamates; Cholinesterase In | 2000 |
Rivastigmine: new product. No better than donepezil.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Indans; | 1999 |
Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.
Topics: Acetylcholine; Administration, Oral; Alzheimer Disease; Animals; Avoidance Learning; Brain Chemistry | 2000 |
FDA approves new cholinesterase inhibitor for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Un | 2000 |
Relation between cholinesterase inhibitor and Pisa syndrome.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Dopamine Antagonists; Dys | 2000 |
Third drug to treat Alzheimer's approved.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Drug Approval; Humans; Phenylcarbamates; R | 2000 |
Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Dose-Response Relationship, Drug; Esophageal Diseases; Female; | 2000 |
Rivastigmine (Exelon) for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Dose-Response Re | 2000 |
The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Ga | 2000 |
Alzheimer's disease: translating neurochemical insights into clinical benefits.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Magnetic Reso | 2000 |
The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
Topics: Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantam | 2000 |
A comparison of sleep profiles in patients with dementia with lewy bodies and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; L | 2000 |
Inhibition of AChE: structure-activity relationship among conformational transition of Trp84 and biomolecular rate constant.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Carbamates; Cholinesterase Inhibito | 2000 |
Cholinesterase inhibitors: expanding applications.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Lewy Body Disease; Phenylcarbamate | 2000 |
Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications.
Topics: Aged; Alzheimer Disease; Canada; Carbamates; Caregivers; Cognition; Cost of Illness; Delivery of Hea | 2000 |
Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cost Savings; Humans; Neuroprotectiv | 2000 |
Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Animals; Benzazepines; Brain; Butyrylcholi | 2000 |
Requirement for presenilin 1 in facilitating lagged 2-mediated endoproteolysis and signaling of notch 1.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; As | 2000 |
Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Galant | 2001 |
Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels.
Topics: Alzheimer Disease; Animals; Arginine; Aspartic Acid; Carbamates; Cholinesterase Inhibitors; Citrulli | 2001 |
Medications for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Donepezil; Estrogen Replacem | 2001 |
Rivastigmine in the treatment of Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; | 2001 |
Featured CME topic: dementia. Medication update.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Contraindications; Donepezil; Drug Interac | 2001 |
Adverse reactions to rivastigmine in three cases of dementia.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Alzheimer Disease; Carbamates; Cholinesterase Inhi | 2001 |
Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inh | 2001 |
Maintaining functional and behavioral abilities in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; | 2001 |
Erythematous maculopapular eruption due to rivastigmine therapy.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Parapsoriasis; Pheny | 2001 |
Rivastagmine-induced agitation following transient recollection of autobiographical memory.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Phenylcarbamates; Ps | 2001 |
Phase I metabolism of ganstigmine. Rat, dog, monkey and human liver microsomal extracts investigated by liquid chromatography electrospray tandem mass spectrometry.
Topics: Alkaloids; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Chromatography, High P | 2001 |
[Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase I | 2002 |
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Confidence Intervals; Donepezil; Galantami | 2001 |
Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; France; Galantam | 2001 |
Presenilin-dependent gamma-secretase activity modulates neurite outgrowth.
Topics: Adaptor Proteins, Signal Transducing; Adult; Alzheimer Disease; Amyloid Precursor Protein Secretases | 2002 |
Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Administration, Oral; Alzheimer Disease; Animals; Brain; Carbamates; Cholinest | 2002 |
[Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; | 2002 |
Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female | 2002 |
Rivastigmin and impaired motor function.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Catatonia; Dyskinesia, Drug-Induced; Female; | 2002 |
[Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Caregivers; Chol | 2002 |
Prolonged QT interval with rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Long QT Syndrome; Male; Neur | 2002 |
Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Carbamates; Cholinesterase Inhibit | 2001 |